INSMED INC Accretion Expense
INSMED INC (INSM) reported Accretion Expense of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:AccretionExpense · last filed 2024-02-22
- INSMED INC accretion expense for the quarter ending 2019-03-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC accretion expense for the quarter ending 2018-12-31 was $0.00, a 100.00% decline year-over-year.
- INSMED INC accretion expense for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC accretion expense for the quarter ending 2018-06-30 was $0.00, a 100.00% decline year-over-year.
- INSMED INC accretion expense for fiscal 2023 was $0.00.
- INSMED INC accretion expense for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- INSMED INC accretion expense for fiscal 2021 was $29.15M, a 53.57% increase from fiscal 2020.
- INSMED INC accretion expense for fiscal 2020 was $18.98M.
| Period end | Accretion Expense 3 month | Accretion Expense 6 month | Accretion Expense 9 month | Accretion Expense 12 month |
|---|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2022-12-31 | $0.00 10-K · filed 2024-02-22 | |||
| 2021-12-31 | $29.15M 10-K · filed 2024-02-22 | |||
| 2020-12-31 | $18.98M 10-K · filed 2023-02-23 | |||
| 2019-03-31 | $0.00 10-Q · filed 2019-05-07 | $0.00 derived: sum of 2 quarters · filed 2019-05-07 | $0.00 derived: sum of 3 quarters · filed 2019-05-07 | $0.00 derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $0.00 derived: sum of 2 quarters · filed 2019-02-22 | $0.00 derived: sum of 3 quarters · filed 2019-02-22 | $50.00K 10-K · filed 2019-02-22 |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $0.00 derived: sum of 2 quarters · filed 2018-10-30 | $50.00K 10-Q · filed 2018-10-30 | $202.00K derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $50.00K 10-Q · filed 2018-08-02 | $202.00K derived: sum of 3 quarters · filed 2019-05-07 | $366.00K derived: sum of 4 quarters · filed 2019-05-07 |
| 2018-03-31 | $50.00K 10-Q · filed 2019-05-07 | $202.00K derived: sum of 2 quarters · filed 2019-05-07 | $366.00K derived: sum of 3 quarters · filed 2019-05-07 | $537.00K derived: sum of 4 quarters · filed 2019-05-07 |
| 2017-12-31 | $152.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $316.00K derived: sum of 2 quarters · filed 2019-02-22 | $487.00K derived: sum of 3 quarters · filed 2019-02-22 | $658.00K 10-K · filed 2019-02-22 |
| 2017-09-30 | $164.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-30 | $335.00K derived: sum of 2 quarters · filed 2018-10-30 | $506.00K 10-Q · filed 2018-10-30 | $677.00K derived: sum of 4 quarters · filed 2019-02-22 |
| 2017-06-30 | $171.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $342.00K 10-Q · filed 2018-08-02 | $513.00K derived: sum of 3 quarters · filed 2019-02-22 | |
| 2017-03-31 | $171.00K 10-Q · filed 2018-05-02 | $342.00K derived: sum of 2 quarters · filed 2019-02-22 | ||
| 2016-12-31 | $171.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $171.00K 10-K · filed 2019-02-22 | ||
| 2016-09-30 | $0.00 10-Q · filed 2017-11-02 | |||
| 2015-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $38.00K derived: sum of 2 quarters · filed 2018-02-23 | $49.00K derived: sum of 3 quarters · filed 2018-02-23 | $76.00K 10-K · filed 2018-02-23 |
| 2015-09-30 | $19.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | $30.00K derived: sum of 2 quarters · filed 2016-11-03 | $57.00K 10-Q · filed 2016-11-03 | $81.00K derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-06-30 | $11.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | $38.00K 10-Q · filed 2016-08-04 | $62.00K derived: sum of 3 quarters · filed 2017-02-23 | $86.00K derived: sum of 4 quarters · filed 2017-02-23 |
| 2015-03-31 | $27.00K 10-Q · filed 2016-05-05 | $51.00K derived: sum of 2 quarters · filed 2017-02-23 | $75.00K derived: sum of 3 quarters · filed 2017-02-23 | $104.00K derived: sum of 4 quarters · filed 2017-02-23 |
| 2014-12-31 | $24.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-23 | $48.00K derived: sum of 2 quarters · filed 2017-02-23 | $77.00K derived: sum of 3 quarters · filed 2017-02-23 | $110.00K 10-K · filed 2017-02-23 |
| 2014-09-30 | $24.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $53.00K derived: sum of 2 quarters · filed 2015-11-06 | $86.00K 10-Q · filed 2015-11-06 | $120.00K derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-06-30 | $29.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | $62.00K 10-Q · filed 2015-08-06 | $96.00K derived: sum of 3 quarters · filed 2016-02-25 | $125.00K derived: sum of 4 quarters · filed 2016-02-25 |
| 2014-03-31 | $33.00K 10-Q · filed 2015-05-07 | $67.00K derived: sum of 2 quarters · filed 2016-02-25 | $96.00K derived: sum of 3 quarters · filed 2016-02-25 | $144.00K derived: sum of 4 quarters · filed 2016-02-25 |
| 2013-12-31 | $34.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-25 | $63.00K derived: sum of 2 quarters · filed 2016-02-25 | $111.00K derived: sum of 3 quarters · filed 2016-02-25 | $160.00K 10-K · filed 2016-02-25 |
| 2013-09-30 | $29.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06 | $77.00K derived: sum of 2 quarters · filed 2014-11-06 | $126.00K 10-Q · filed 2014-11-06 | |
| 2013-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-06 | $97.00K 10-Q · filed 2014-08-06 | ||
| 2013-03-31 | $49.00K 10-Q · filed 2014-05-08 | |||
| 2012-12-31 | $44.00K 10-K · filed 2015-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |